Antiphospholipid antibodies in patients with stroke during COVID-19: A role in the signaling pathway leading to platelet activation
BackgroundSeveral viral and bacterial infections, including COVID-19, may lead to both thrombotic and hemorrhagic complications. Previously, it has been demonstrated an “in vitro” pathogenic effect of “antiphospholipid” antibodies (aPLs), which are able to activate a proinflammatory and procoagulant...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1129201/full |
| _version_ | 1811161764366123008 |
|---|---|
| author | Antonella Capozzi Gloria Riitano Serena Recalchi Valeria Manganelli Agostina Longo Anne Falcou Manuela De Michele Tina Garofalo Fabio M. Pulcinelli Maurizio Sorice Roberta Misasi |
| author_facet | Antonella Capozzi Gloria Riitano Serena Recalchi Valeria Manganelli Agostina Longo Anne Falcou Manuela De Michele Tina Garofalo Fabio M. Pulcinelli Maurizio Sorice Roberta Misasi |
| author_sort | Antonella Capozzi |
| collection | DOAJ |
| description | BackgroundSeveral viral and bacterial infections, including COVID-19, may lead to both thrombotic and hemorrhagic complications. Previously, it has been demonstrated an “in vitro” pathogenic effect of “antiphospholipid” antibodies (aPLs), which are able to activate a proinflammatory and procoagulant phenotype in monocytes, endothelial cells and platelets. This study analyzed the occurrence of aPL IgG in patients with acute ischemic stroke (AIS) during COVID-19, evaluating the effect of Ig fractions from these patients on signaling and functional activation of platelets.Materials and methodsSera from 10 patients with AIS during COVID-19, 10 non-COVID-19 stroke patients, 20 COVID-19 and 30 healthy donors (HD) were analyzed for anti-cardiolipin, anti-β2-GPI, anti-phosphatidylserine/prothrombin and anti-vimentin/CL antibodies by ELISA. Platelets from healthy donors were incubated with Ig fractions from these patients or with polyclonal anti-β2-GPI IgG and analyzed for phospho-ERK and phospho-p38 by western blot. Platelet secretion by ATP release dosage was also evaluated.ResultsWe demonstrated the presence of aPLs IgG in sera of patients with AIS during COVID-19. Treatment with the Ig fractions from these patients or with polyclonal anti-β2-GPI IgG induced a significant increase of phospho-ERK and phospho-p38 expression. In the same vein, platelet activation was supported by the increase of adenyl nucleotides release induced by Ig fractions.ConclusionsThis study demonstrates the presence of aPLs in a subgroup of COVID-19 patients who presented AIS, suggesting a role in the mechanisms contributing to hypercoagulable state in these patients. Detecting these antibodies as a serological marker to check and monitor COVID-19 may contribute to improve the risk stratification of thromboembolic manifestations in these patients. |
| first_indexed | 2024-04-10T06:19:26Z |
| format | Article |
| id | doaj.art-55e066f3b315407ea5cf5b6dd849935f |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T06:19:26Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-55e066f3b315407ea5cf5b6dd849935f2023-03-02T05:01:41ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.11292011129201Antiphospholipid antibodies in patients with stroke during COVID-19: A role in the signaling pathway leading to platelet activationAntonella Capozzi0Gloria Riitano1Serena Recalchi2Valeria Manganelli3Agostina Longo4Anne Falcou5Manuela De Michele6Tina Garofalo7Fabio M. Pulcinelli8Maurizio Sorice9Roberta Misasi10Department of Experimental Medicine, “Sapienza” University of Rome, Rome, ItalyDepartment of Experimental Medicine, “Sapienza” University of Rome, Rome, ItalyDepartment of Experimental Medicine, “Sapienza” University of Rome, Rome, ItalyDepartment of Experimental Medicine, “Sapienza” University of Rome, Rome, ItalyDepartment of Experimental Medicine, “Sapienza” University of Rome, Rome, ItalyEmergency Department, “Sapienza” University of Rome, Rome, ItalyEmergency Department, “Sapienza” University of Rome, Rome, ItalyDepartment of Experimental Medicine, “Sapienza” University of Rome, Rome, ItalyDepartment of Experimental Medicine, “Sapienza” University of Rome, Rome, ItalyDepartment of Experimental Medicine, “Sapienza” University of Rome, Rome, ItalyDepartment of Experimental Medicine, “Sapienza” University of Rome, Rome, ItalyBackgroundSeveral viral and bacterial infections, including COVID-19, may lead to both thrombotic and hemorrhagic complications. Previously, it has been demonstrated an “in vitro” pathogenic effect of “antiphospholipid” antibodies (aPLs), which are able to activate a proinflammatory and procoagulant phenotype in monocytes, endothelial cells and platelets. This study analyzed the occurrence of aPL IgG in patients with acute ischemic stroke (AIS) during COVID-19, evaluating the effect of Ig fractions from these patients on signaling and functional activation of platelets.Materials and methodsSera from 10 patients with AIS during COVID-19, 10 non-COVID-19 stroke patients, 20 COVID-19 and 30 healthy donors (HD) were analyzed for anti-cardiolipin, anti-β2-GPI, anti-phosphatidylserine/prothrombin and anti-vimentin/CL antibodies by ELISA. Platelets from healthy donors were incubated with Ig fractions from these patients or with polyclonal anti-β2-GPI IgG and analyzed for phospho-ERK and phospho-p38 by western blot. Platelet secretion by ATP release dosage was also evaluated.ResultsWe demonstrated the presence of aPLs IgG in sera of patients with AIS during COVID-19. Treatment with the Ig fractions from these patients or with polyclonal anti-β2-GPI IgG induced a significant increase of phospho-ERK and phospho-p38 expression. In the same vein, platelet activation was supported by the increase of adenyl nucleotides release induced by Ig fractions.ConclusionsThis study demonstrates the presence of aPLs in a subgroup of COVID-19 patients who presented AIS, suggesting a role in the mechanisms contributing to hypercoagulable state in these patients. Detecting these antibodies as a serological marker to check and monitor COVID-19 may contribute to improve the risk stratification of thromboembolic manifestations in these patients.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1129201/fullantiphospholipid antibodiesβ2-GPICOVID-19thrombosisstroke. |
| spellingShingle | Antonella Capozzi Gloria Riitano Serena Recalchi Valeria Manganelli Agostina Longo Anne Falcou Manuela De Michele Tina Garofalo Fabio M. Pulcinelli Maurizio Sorice Roberta Misasi Antiphospholipid antibodies in patients with stroke during COVID-19: A role in the signaling pathway leading to platelet activation Frontiers in Immunology antiphospholipid antibodies β2-GPI COVID-19 thrombosis stroke. |
| title | Antiphospholipid antibodies in patients with stroke during COVID-19: A role in the signaling pathway leading to platelet activation |
| title_full | Antiphospholipid antibodies in patients with stroke during COVID-19: A role in the signaling pathway leading to platelet activation |
| title_fullStr | Antiphospholipid antibodies in patients with stroke during COVID-19: A role in the signaling pathway leading to platelet activation |
| title_full_unstemmed | Antiphospholipid antibodies in patients with stroke during COVID-19: A role in the signaling pathway leading to platelet activation |
| title_short | Antiphospholipid antibodies in patients with stroke during COVID-19: A role in the signaling pathway leading to platelet activation |
| title_sort | antiphospholipid antibodies in patients with stroke during covid 19 a role in the signaling pathway leading to platelet activation |
| topic | antiphospholipid antibodies β2-GPI COVID-19 thrombosis stroke. |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1129201/full |
| work_keys_str_mv | AT antonellacapozzi antiphospholipidantibodiesinpatientswithstrokeduringcovid19aroleinthesignalingpathwayleadingtoplateletactivation AT gloriariitano antiphospholipidantibodiesinpatientswithstrokeduringcovid19aroleinthesignalingpathwayleadingtoplateletactivation AT serenarecalchi antiphospholipidantibodiesinpatientswithstrokeduringcovid19aroleinthesignalingpathwayleadingtoplateletactivation AT valeriamanganelli antiphospholipidantibodiesinpatientswithstrokeduringcovid19aroleinthesignalingpathwayleadingtoplateletactivation AT agostinalongo antiphospholipidantibodiesinpatientswithstrokeduringcovid19aroleinthesignalingpathwayleadingtoplateletactivation AT annefalcou antiphospholipidantibodiesinpatientswithstrokeduringcovid19aroleinthesignalingpathwayleadingtoplateletactivation AT manuelademichele antiphospholipidantibodiesinpatientswithstrokeduringcovid19aroleinthesignalingpathwayleadingtoplateletactivation AT tinagarofalo antiphospholipidantibodiesinpatientswithstrokeduringcovid19aroleinthesignalingpathwayleadingtoplateletactivation AT fabiompulcinelli antiphospholipidantibodiesinpatientswithstrokeduringcovid19aroleinthesignalingpathwayleadingtoplateletactivation AT mauriziosorice antiphospholipidantibodiesinpatientswithstrokeduringcovid19aroleinthesignalingpathwayleadingtoplateletactivation AT robertamisasi antiphospholipidantibodiesinpatientswithstrokeduringcovid19aroleinthesignalingpathwayleadingtoplateletactivation |